Clinical Competition Candidate

FABIOR

Dermatology · Acne vulgaris (tazarotene foam)

FABIOR carries product and use-code patents, moderate complexity (2/5), and meaningful clinical competition (4/5). The listed expiry window is approximately 44 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

44months

to latest listed patent expiry (February 24, 2030)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (listed)

Patent count: 3

Complexity score: 2/5

Clinical competition

Score: 4/5

Active trials linked: 68

Phase 2/3 trials: 32

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: TAZAROTENE

Applicant (NDA holder): MAYNE PHARMA LLC

Confidence: High

Market context

Therapeutic area: Dermatology

Indication: Acne vulgaris (tazarotene foam)

U.S. market size (est.)< $100M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.